Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Epetraborole

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AN2 Therapeutics Reports Q4 and FY 2025 Financial Results
    AN2 Therapeutics Reports Q4 and FY 2025 Financial Results

    17 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260317440715/en/AN2-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Business-and-Scientific-Highlights

    BUSSINESSWIRE
    17 Mar 2026
    Share Share
    AN2 Therapeutics To Progress Oral Epetraborole Into Phase 2
    AN2 Therapeutics To Progress Oral Epetraborole Into Phase 2

    03 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260303819156/en/AN2-Therapeutics-Announces-Plans-to-Advance-Oral-Epetraborole-into-Phase-2-Study-for-Polycythemia-Vera-PV

    BUSINESSWIRE
    03 Mar 2026
    Share Share
    AN2 Therapeutics To Launch 90-Patient Trial For Epetraborole
    AN2 Therapeutics To Launch 90-Patient Trial For Epetraborole

    12 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260112479198/en/AN2-Therapeutics-Announces-FDA-Clearance-to-Proceed-with-90-Patient-Investigator-Initiated-Trial-IIT-of-Epetraborole-in-Patients-with-M.-abscessus-Lung-Disease

    BUSINESSWIRE
    12 Jan 2026
    Share Share
    AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights
    AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights

    13 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240813783660/en

    BUSINESSWIRE
    13 Aug 2024
    Share Share
    AN2 Therapeutics shares fall after pausing lung disease study enrollment
    AN2 Therapeutics shares fall after pausing lung disease study enrollment

    13 Feb 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/an2-therapeutics-pause-lung-disease-study-enrollment-2024-02-12/

    REUTERS
    13 Feb 2024
    Share Share
    AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole
    AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole

    13 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230913252729/en

    BUSINESSWIRE
    13 Sep 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.